Insmed Incorporated reported results from the Company's phase 2 clinical trial of ARIKAYCETM, or liposomal amikacin for inhalation, for the treatment of patients with treatment resistant nontuberculous mycobacterial (NTM) lung infections. The randomized, double-blind, placebo-controlled phase 2 clinical trial compared ARIKAYCE (590 mg delivered once daily), added to standard of care treatment, versus standard of care treatment plus placebo, in 90 adult patients with treatment resistant NTM lung disease. Eligibility for the study required patients to have been on the American Thoracic Society/Infectious Disease Society of America (ATS/IDSA) guideline therapy for at least six months prior to screening and to continue to have persistently positive mycobacterial cultures.
The primary efficacy endpoint of the study was a semi-quantitative measurement of the change in mycobacterial density on a seven-point scale from baseline (day one) to the end of the randomized portion of the trial (day 84). ARIKAYCE did not meet the pre-specified level for statistical significance
Patients receiving ARIKAYCE experienced a greater number of adverse events than those receiving placebo. All adverse events experienced with ARIKAYCE were consistent with those seen in similar patient populations receiving inhaled antibiotics. The most common side effect was laryngeal irritation.
Insmed (NASDAQ:INSM) was downgraded by Zacks from a “buy” rating to a “hold” rating in a report released
In other Insmed news, VP Mark Quigley sold 18,750 shares of the stock in a transaction dated Tuesday, . The stock was sold at an average price of $22.07, for a total transaction of $413,812.50. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link.
Shares of Insmed (NASDAQ:INSM) traded up 2.23% during mid-day trading on Tuesday, hitting $26.58. 230,676 shares of the company’s stock traded hands. Insmed has a 52 week low of $11.25 and a 52 week high of $26.77. The stock’s 50-day moving average is $24.22 and its 200-day moving average is $20.70. The company’s market cap is $1.63 billion.
Insmed (NASDAQ:INSM) last issued its quarterly earnings data on Thursday, May 7th. The biopharmaceutical company reported ($0.55) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.49) by $0.06. On average, analysts predict that Insmed will post $-1.96 earnings per share for the current fiscal year.
A number of other firms have also recently commented on INSM. Analysts at Citigroup Inc.initiated coverage on shares of Insmed in a research note on Tuesday, June 9th. They set a “neutral” rating and a $27.00 price target on the stock. Analys
blasedp31 aka fud4 aka jad9000 • May 13, 2013 4:47 PM " 2 years is too long !
"I'm currently in discussion with the global Stop TB Partnership, advising them how they should redesign
their various therapeutic regimens now that Arikace is available.When they've finally grasped what they should be doing I'll get in touch with Insmed and give them the benefit of my advice."
Tuberculosis (TB) Treatment
Can't help but think that Insmed will consider Arikayce will be more helpful than the injectable amikacin for TB patients:
With appropriate antibiotic treatment, TB can be cured in most people. Successful treatment of TB depends on close cooperation between patients and healthcare providers. Treatment usually involves taking several antibiotic drugs for at least 6 months and sometimes for as long as 12 months.
Antibiotic Resistance and the Importance of Finishing the TB Medicine
People who do not take all the required medicines can become sick again and spread TB to others. Additionally, when people do not take all the prescribed medicines or skip times when they are supposed to take them, the TB bacteria evolve to outwit the TB antibiotics. Soon those medicines no longer work against the disease. If this happens, the person now has drug-resistant TB. Additionally, some people with TB do not get better with treatment because their disease is caused by a strain of the TB bacterium that is already resistant to one or more of the standard TB drugs.
Multidrug-resistant TB (MDR TB) is TB that is resistant to at least two of the best Food and Drug Administration-approved anti-TB drugs, isoniazid and rifampicin. These antibiotics are considered first-line drugs and are the first medicines used to treat all persons with TB disease. Extensively drug-resistant TB (XDR TB) is a relatively rare type of TB that is resistant to isoniazid and rifampin, plus any fluoroquinolone and at least one of three injectable second-line drugs
Terry "didnt post all weekend , but I did . How come you cant read?
You are very stupid , You will learn
INSM GLBT Club was established for our persuasion but all are invited! INSMED SUBJECTS
Average analyst say $26 is the top! till next years decision
34 MEMBERS Strong
depends if the News is bad or good
NEWS is great for our club kvncmcdd Thanks for all you do
Im straight but respect you and your boys
Lets get going
Price target $17
jad9000 , You so need to get a life! Your obsession with terry_insm is obvious. You know nothing about the short interest is one reason. I am not him, but enjoy watching him making you look like a fool over and over. You can not guess in investing, but you are guessing. Have a nice day
example : On May 1, the stock jumped $1.20 and of course ... "jad9000 • May 1, 2015 " they are short, but they may have covered a million shares"
terry_insm • May 4, 2015 10:14 AM "guess again Evelyn! (jad9000) .... the short interest is adding, I guarantee it. " ...
and as the numbers last week showed, they indeed added for that week and the next week, to the tune of 500,000 + shares
Reply to Question - Now What? by insmhistorian [portend a bullish trend,]
Terry NEVER said that. You dont know what you are talking about.
"jad9000 • Feb 11, 2015 " So, 2016 would be a market of 17,500 at a price of around $50,000 annually or slightly under $900 million. All of the EU would be then be around 35,000 cases at $50,000 annually, or $1.75 billion. Then we add in CF, Japan with their 35,000 cases (40,000 by 2016) and the year after the US market around 35,000 (also 40,000 by 2016). That's quite a few billions of dollars by the end of 2016"